Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1994-12-02
1997-12-23
Loring, Susan A.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241301, 4241411, 4241501, 4241581, 5303871, 5303881, 5303882, 53038823, 5303884, A61K 39395, A61K 3940, A61K 3819, C07K 1624
Patent
active
057004668
ABSTRACT:
The present invention pertains to the novel hybridoma SDW18.1.1, hybridomas obtained from SDW18.1.1, monoclonal antibodies obtained from such hybridomas and derivatives of such monoclonal antibodies. The novel hybridomas are formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with cachectin/TNF. Diagnostic and therapeutic utilities for the monoclonal antibodies and their derivatives are proposed, and testing procedures, materials in kit form and pharmaceutical compositions are likewise set forth.
REFERENCES:
patent: 5231024 (1993-07-01), Moeller et al.
Abraham, E. et al., Jama, 273(12):934-941, Mar. 1995.
Natanson, C. et al., Annals of Int. Med., 120(9):771-783, 1 May 1994.
Cross, A.S. et al., Inf. & Immun., 61(7):2741-2747, Jul. 1993.
Makato Hirai et al., Production & characterization of monoclonal anti-bodies to human tumor necrosis factor, JOURNAL OF IMMUNOLOGICAL METHODS, 96 (1987), 57-62.
Chi-Ming Liang et al., Production & characterization of monoclonal anti-bodies against recombinant human tumor necrosis factor/cachectin, BIOCHEMICAL & BIOPHYSICAL RESEARCH COMMUNICATION, vol. 137, No. 2 (1986).
Daniela N. Mannel et al., Inhibition of nonspecific tumoricidal activity by activated macrophages with antiserum against a soluble cytotoxic factor, INFECTION AND IMMUNITY (Jul., 1981), 156-164.
Bong-Sop Shim et al., The nature of endotoxin-induced tumor necrosis factor, BIOLOGICAL ABSTRACTS, vol. 69, No. 2 (Jan. 15, 1980).
Tracey, et al., 1986, "Shock and Tissue Injury Induced by . . . " Science 234: 470-474.
Bentler, et al., 1985 "Passive Immunization Against Cachectin 1 tumor necrosis factor . . . " Science 229: 869-871.
Bringman et al., 1987 "Monoclonal antibodies to human tumor necrosis factors . . . " Hybridoma 6(5): 489-507.
Mc Namara, et al., 1984, "Monoclonal Idiotope Vaccine . . . " Science 220: 1325-1326.
Fink, et al, 1990, "Laboratory models of Sepsis . . . " J. Surgical Res 49: 186-196.
Verhoef, et al, 1990, "Prospects for monoclonal antibodies . . . " Eur. J. Clin. Microbiol. Infect. Dis. 9(4): 247-250.
Fitzer-Schiller, 1993 "Centocor Stops trials of Flagship Drug"Wash. Post Jan. 18, 1993.
Stone, 1993, "Biotec Industry Reels on Sepsis".
Cerami Anthony
Wolpe Stephen D.
Loring Susan A.
The Rockefeller University
LandOfFree
Method of ameliorating or preventing septic shock using a monocl does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of ameliorating or preventing septic shock using a monocl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of ameliorating or preventing septic shock using a monocl will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1800421